After $59M round, CRISPR startup launches with plans to tackle heart disease
A new gene editing company, founded by two Harvard scientists and one of the men behind Editas Medicine, has launched with nearly $59 million to develop a single treatment for the leading cause of death worldwide.
Verve Therapeutics emerged from stealth mode this week after a Series A financing round led by GV, formerly Google Ventures. The 10-person startup has also signed collaboration deals with fellow gene editing startup Beam Therapeutics and Verily, a life science business operating under…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Genetics | Harvard | Health Management | Heart | Heart Disease | Pharmaceuticals | Science